This systematic review identified only one randomised controlled trial (Dharmaraj et al. 2009 [11]) that met full inclusion criteria for assessing the effectiveness and safety of intravenous albumin in hospitalised children with nephrotic syndrome and oedema. The gene discussed is ALB; the disease is nephrotic syndrome.